ASCO: Two-Year Survival Seen with Sutent in Kidney Cancer

0 Views
administrator
administrator
07/10/23

http://www.medpagetoday.com
Robert A. Figlin, M.D., City of Hope, Duarte, Calif.

CHICAGO -- In patients with treatment-naive advanced renal cell carcinoma, treatment with sunitinib (Sutent) more than doubled progression-free survival compared with interferon alfa.

Medpage Today: http://medpagetoday.com
Online CME - Continuing medical education: http://www.medpagetoday.com/cme/
Latest medical news: http://www.medpagetoday.com/latest/

The MedPage Today app:
iOS: https://goo.gl/JKrkHq
Android: https://play.google.com/store/....apps/details?id=com.

MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageToday
Medpage Today on Facebook: https://www.facebook.com/MedPageToday

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next